7 studies found for:    xmab5574
Show Display Options
Rank Status Study
1 Completed Safety and Tolerability of XmAb®5574 in Chronic Lymphocytic Leukemia
Conditions: Chronic Lymphocytic Leukemia;   Small Lymphocytic Lymphoma
Intervention: Biological: XmAb5574
2 Recruiting A Trial to Evaluate the Efficacy and Safety of MOR208 With Bendamustine (BEN) Versus Rituximab (RTX) With BEN in Adult Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL)
Condition: Diffuse Large B-cell Lymphoma
Interventions: Drug: Rituximab (RTX);   Drug: MOR208;   Drug: Bendamustine (BEN)
3 Terminated Study of Fc-Optimized Anti-CD19 Antibody (MOR00208) to Treat B-cell Acute Lymphoblastic Leukemia(B-ALL)
Condition: Acute Lymphoblastic Leukemia
Intervention: Drug: MOR00208 (formerly Xmab5574)
4 Active, not recruiting Study of Fc-Optimized Anti-CD19 Antibody (MOR00208) to Treat Non-Hodgkin´s Lymphoma (NHL)
Condition: Non-Hodgkin Lymphoma
Intervention: Drug: MOR00208 (formerly Xmab 5574)
5 Not yet recruiting Study to Evaluate Efficacy and Safety of MOR208 With Idelalisib in R/R CLL/SLL Patients Pretreated With BTKi
Conditions: Leukemia, Lymphocytic, Chronic, B-Cell;   Chronic Lymphocytic Leukemia;   Small Lymphocytic Lymphoma
Interventions: Biological: MOR00208;   Drug: idelalisib
6 Recruiting Phase II MOR00208 in Combination With Lenalidomide for Patients With Relapsed or Refractory CLL, SLL or PLL or Older Patients With Untreated CLL, SLL or PLL
Conditions: Contiguous Stage II Small Lymphocytic Lymphoma;   Noncontiguous Stage II Small Lymphocytic Lymphoma;   Prolymphocytic Leukemia;   Recurrent Small Lymphocytic Lymphoma;   Refractory Chronic Lymphocytic Leukemia;   Stage I Chronic Lymphocytic Leukemia;   Stage I Small Lymphocytic Lymphoma;   Stage II Chronic Lymphocytic Leukemia;   Stage III Chronic Lymphocytic Leukemia;   Stage III Small Lymphocytic Lymphoma;   Stage IV Chronic Lymphocytic Leukemia;   Stage IV Small Lymphocytic Lymphoma
Interventions: Biological: MOR00208;   Drug: lenalidomide;   Other: Correlative Studies
7 Recruiting A Study to Evaluate the Safety and Efficacy of Lenalidomide With MOR00208 in Patients With R-R DLBCL
Condition: Diffuse Large B-cell Lymphoma
Interventions: Drug: MOR00208;   Drug: Lenalidomide

Indicates status has not been verified in more than two years